Additionally, 17 potential therapeutic targets (AKT1, CCND1, CASP3, CTNNB1, EGF, EGFR, ESR1, HIF1A, HSP90AA1, IL6, JUN, MYC, MAPK3, PTEN, STAT3, TP53, VEGFA) were directly related to the KEGG pathway “cancer” and linked to 30 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZJ6, CL2, ZJ10, ZJ12, ZJ2, DSL4, DSL5, DSL6, ZZS1, CF1, CF10, GC12, GC16, GC37, QYS3, SQ13, XYS24, CBM16; Table S2). This evidence concerns the gene AKT1 and cancer.